Quantcast
Last updated on April 16, 2014 at 7:00 EDT

Latest Deep vein thrombosis Stories

2014-01-16 23:00:31

The DrugRisk Center is the largest source on the Web for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com Orlando, FL (PRWEB) January 16, 2014 The birth control safety advocates at DrugRisk.com are now offering help to patients who have taken Yaz or Yasmin with questions about settlements. This is in addition to information on the site about the latest research, warnings and legal news on contraceptives like Yaz that use the hormone...

2014-01-08 23:00:18

A NuvaRing lawsuit recently filed by Wright & Schulte alleges that a Florida woman developed deep vein thrombosis and pulmonary embolism due to her use of NuvaRing. Columbus, OH (PRWEB) January 08, 2014 Wright & Schulte is currently representing a woman from Cape Coral, Florida in a recently filed NuvaRing lawsuit (Case No. 2:13-cv-00721-SPC-DNF). This case, which was filed in the U.S. District Court of Ohio, contends that the plaintiff developed serious blood clotting disorders...

2014-01-08 12:30:25

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and PARSIPPANY, N.J., Jan. 8, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the New Drug Application (NDA) for its investigational, oral, once-daily direct factor Xa-inhibitor SAVAYSA(TM) (edoxaban) Tablets has been submitted to the U.S. Food...

2014-01-07 23:00:15

The DrugRisk Center is the largest source on the Web for information on prescription drug research, side effects and legal news. Visit http://www.DrugRisk.com Chicago, IL (PRWEB) January 07, 2014 For 2014, the prescription drug safety advocates at DrugRisk.com have launched a new patient resource center for women who have taken the birth control pills Yaz or Yasmin. The site will offer the latest research, warnings and legal news on contraceptives like Yaz that use the hormone...

2014-01-07 12:28:27

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and MUNICH, Jan. 7, 2014 /PRNewswire/ -- Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application (MAA) for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency...

2013-12-31 23:23:32

Siragusa Vein & Laser Center released an article to tell future patients the benefits of seeing a vein doctor and the hazards of not seeking treatment for problematic veins. Nashville, TN (PRWEB) December 31, 2013 Siragusa Vein and Laser Center has published a new article to educate the public on the importance of seeing a spider and varicose veins doctor in Nashville when the health of their veins is at risk. According to the Nashville vein center, doctors who specialize in vascular...

2013-12-20 23:22:59

The Drug Risk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com Kansas City, MO (PRWEB) December 20, 2013 The birth control safety center DrugRisk.com is announcing updated information for women using the contraceptive NuvaRing. Court records for December show the number of lawsuits alleging the device caused blood clot-related injuries has risen*. DrugRisk is a free resource for those...

2013-12-19 08:26:43

-- Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO, Dec. 19, 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (NDA) for its oral, once-daily direct factor Xa-inhibitor LIXIANA(®) (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry...

2013-12-18 23:28:27

National network of lawyers will continue offer of these consultations through Christmas and New Year’s Day. Allegations being reviewed include migrations, perforation, filter fracture and other problems linked by FDA to life-threatening health problems. San Diego, CA (PRWEB) December 18, 2013 http://www.resource4thepeople.com/defectivemedicaldevices/bard-ivc.html Resource4thePeople announced today that its national network of attorneys will be available over the upcoming holiday...

2013-12-17 08:28:51

RE-COVER II(TM) trial shows dabigatran non-inferior to warfarin in preventing recurrent DVT and/or PE and related death, with a reduction in major or clinically relevant non-major bleeding RIDGEFIELD, Conn., Dec. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the RE-COVER(TM) II study evaluating dabigatran compared to warfarin in patients diagnosed with acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE). In this Phase III study,...